S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Miragen Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-1.08 (-5.57%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
11,206 shs
Average Volume
134,027 shs
Market Capitalization
$71.52 million
P/E Ratio
Dividend Yield

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Miragen Therapeutics logo

About Miragen Therapeutics

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.


Miragen Therapeutics EPS beats by $0.03
November 10, 2020 |  seekingalpha.com
Miragen Therapeutics Inc
November 1, 2020 |  bloomberg.com
Why Miragen's Stock Is Trading Higher Today
October 28, 2020 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$4.46 million
Book Value
$6.78 per share


Net Income
$-41.87 million
Net Margins
Pretax Margin




Free Float
Market Cap
$71.52 million
Not Optionable

Company Calendar

Last Earnings


Overall MarketRank

1.76 out of 5 stars

Medical Sector

871st out of 1,391 stocks

Medical Laboratories Industry

20th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

Is Miragen Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Miragen Therapeutics stock.
View analyst ratings for Miragen Therapeutics
or view top-rated stocks.

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics, Inc. (NASDAQ:MGEN) posted its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%.
View Miragen Therapeutics' earnings history

What price target have analysts set for MGEN?

2 brokers have issued 1 year target prices for Miragen Therapeutics' shares. Their forecasts range from $37.00 to $37.00. On average, they anticipate Miragen Therapeutics' stock price to reach $37.00 in the next year. This suggests a possible upside of 102.2% from the stock's current price.
View analysts' price targets for Miragen Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Miragen Therapeutics' key executives?

Miragen Therapeutics' management team includes the following people:
  • Mr. Jason A. Leverone CPA, CPA, CFO, Sec. & Treasurer (Age 46, Pay $355k)
  • Dr. William Stuart Marshall Ph.D., Co-Founder & Sr. Technical Advisor (Age 56, Pay $521k)
  • Dr. Diana Escolar, Chief Medical Officer (Age 58, Pay $484.38k)
  • Ms. Lee M. Rauch, CEO & Director (Age 65)
  • Dr. Jonathan Violin Ph.D., Pres & COO (Age 45)
  • Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 75)
  • Dr. Marvin H. Caruthers, Co-Founder & Scientific Advisory Board Member (Age 80)
  • Mr. Vahe Bedian Ph.D., Chief Scientific Officer
  • Dr. Aimee L. Jackson, VP of Research

What other stocks do shareholders of Miragen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Novan (NOVN) and Aeterna Zentaris (AEZS).

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $18.30.

How much money does Miragen Therapeutics make?

Miragen Therapeutics has a market capitalization of $71.52 million and generates $4.46 million in revenue each year. The medical research company earns $-41.87 million in net income (profit) each year or ($20.09) on an earnings per share basis.

How many employees does Miragen Therapeutics have?

Miragen Therapeutics employs 45 workers across the globe.

What is Miragen Therapeutics' official website?

The official website for Miragen Therapeutics is www.signalgenetics.com.

Where are Miragen Therapeutics' headquarters?

Miragen Therapeutics is headquartered at 6200 LOOKOUT ROAD, BOULDER CO, 80301.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.